The 3D curved patch is unique to cardiac aortic arch repair and procedures, Children's hospitals which have the highest cases of aortic arch defect would greatly benefit from 3D NEO. ADMEDUS is dotting the I's and crossing their T's before Officially launching the 3D, by keeping a close eye on product and procedures ADMEDUS is securing their superiority by having feedback at hand by surgeons ( their needs @ wants ) ironing out their path ahead for 3D to become standard procedure.
Once launched, 3D will dominate the repair @ replacement of aortic arch procedures,
Vascucel is growing fast and will dominate as competitors exit. ( BAXTER ) etc
TAVR is FAR superior to competitors products and will disrupt the industry, they call it
DISRUPTIVE TECHNOLOGY. But for ADMEDUS to properly distribute and grow fast they need a big brother ( partnership ) for this ADAPT platform has just begun to grow the last 12 months and will grow even faster the next 12 months being the only BIO TISSUE with ZERO DNA READINGS. ( BOOM )
DYOR
AHZ Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
(20min delay)